Quinolones constitute a large class of antimicrobial drugs with marked activity against Enterobacteriaceae, other Gram-negative bacteria and staphylococci, while streptococci and enterococci have intermediate sensitivity.
The quinolones show a high bioavailability after oral administration and a large volume of distribution, while their protein binding is low or negligible. Despite these positive characteristics a specific contraindication, the fear of a possible effect on the joint cartilage of growing subjects, limits their use to adult patients.
The first indication of a possible arthralgic effect of quinolones was reported with nalidixic acid in 1972 by Bailey, Natale & Linton. As a consequence many toxicological studies have been performed in animals of various species with a wide range of quinolone derivatives: nalidixic acid, pipemidic acid, oxolinic acid, cinoxacin, ciprofloxacin, ofloxacin and pefloxacin (Ingham et ^ 1977 . Bouissou et al.. 1978 Tatsumi et al.. 1978; Gough et al., 1979; Mayer, 1987; Christ, Lehnert & Ulbrich, 1988) . Virtually all quinolones may cause lesions of the major diarthrodial joints when administered to immature or juvenile animals, but the absolute potency of different compounds is quite variable (Schluter, 1987) . The same variability has been observed as far as the sensitivity of different animal species is concerned. Dogs are by far the most sensitive animals; in this species damage to the weightbearing joints occurred in three to four month old puppies after 7-28 days of oral treatment with 20mg/kg/day of ofloxacin or 30mg/kg/day of ciprofloxacin (Mayer, 1987; Christ et al., 1988) ; in four to five week old rats, however, the doses of the same drugs required to obtain similar effects were 100-300 mg/kg/day and 500 mg/kg/day, respectively (Mayer, 1987; Schluter, 1987; Christ et al., 1988) . In addition, the age of the animal is important in determining the arthropathic effect of quinolones. The younger the animal, the worse the lesion and the shorter the interval between drug administration and lesion development. Arthropathic effects have been observed in adult dogs only after chronic (one-year) treatment with an oral dose of 140 mg/kg/day of pefloxacin, and no articular damage has been noted in monkeys treated for the same period with an oral daily dose of 40 mg/kg of the same drug (Mayer, 1987) . The pathogenesis and the biochemical mechanism involved at the molecular level in the development of the arthropathic lesion are still unknown. Morphological findings include erosions of the joint cartilage with blister-like degeneration, accompanied by a cell-free noninflammatory effusion in the joint cavity (HOODCT & Wolfson, 1985; Chevais et al., 1987) . The decomposition of the cartilage matrix can cause an additional irritative reaction of the synovia (Chevais et al., 1987) .
The contraindication to using quinolones in children is essentially based on the results of these phase 1 studies. A direct extrapolation of these results to human beings is not easy to justify, especially considering the wide variability of animal experience and the fact that most animal species were sensitive to doses far above (10-35 times) the clinically recommended ones. Only in the dog, the most sensitive species, were articular lesions observed after treatment with oral doses closer to human ones on a body weight basis (1.5-2 times greater) administered for a period of time that could be compared with the duration of a' common antimicrobial treatment in humans. On the other hand, the difference in doses necessary to induce similar effects in different species might be explicable by the specific pharmacokinetic characteristics in a given species; after administration of the same dose, dogs show the highest peak concentration, the longest half-life and the greatest AUC, in comparison with other species (Okazaki et al., 1984; Stahlmann & Lode, 1988) .
Quinolones have been extensively studied in adult patients and their tolerability has been well documented. In the post-marketing surveillance programme for ofloxacin only 15 spontaneous reports of arthralgia and/or myalgia were received and these data must be viewed in the context of an estimated number of treated patients of 1.5 million (Monk & Campoli-Richards, 1987) . A comprehensive analysis of the clinical data for ciprofloxacin revealed nine cases of arthralgia among 8861 treated patients (Schacht et al.. 1988) . In all subjects clinical symptoms subsided with suspension of therapy and there was no clinically evident sequela (Schacht et al., 1988) . Some safety data on children treated on compassionate grounds are available, too (Redmond et al.. 1987; Schaad & Wedgwood-Krucko, 1987; Scully et al.. 1987; Schaad & Wedgwood-Krucko, 1989 ). The evidence, even if based on a small number of cases, is against a significant arthropathogenic effect of quinolones in this specific population; in the few described cases recovery occurred within a few days after cessation of therapy without any clinically evident consequence (Alfaham, Holt & Goodchild, 1987; Jawad, 1989) . Carefully monitored studies based on more sophisticated techniques, such as magnetic resonance imaging, are needed either to confirm or to dispute the risk of articular changes in young patients, but from the data already available, quinolone use in children should be possible in selected patients in whom the foreseeable benefit of a short-term therapy overrides the possible risk. Some categories of patients are particularly eligible as, for example, subjects affected by cystic fibrosis with an acute exacerbation of pulmonary symptoms (Stem et al., 1984) in whom the aetiological agent is frequently a quinolonesensitive bacterium, such as Pseudomonas aeruginosa or other Gram-negative rod, that has become multiresistant after repeated antibiotic treatment (Bender et al., 1984; Rubio & Shapiro, 1986; Meyer, 1987) . It has been shown that, in adult patients, cystic fibrosis does not influence the pharmacokinetic behaviour of the quinolones (Bender et al., 1986; David et al.. 1987; LeBcl et al., 1988) . It must be pointed out, however, that data concerning the possible cumulative effects of repeated courses of therapy are still lacking. Another specific indication could be infective episodes complicating acute leukemia (Anders et al., 1985; Maggiolo, Bianchi & Ohnmeiss, 1988) . In such cases, hospital-acquired multiresistant strains are often involved and infection by Gram-negative bacteria is particularly dangerous. Furthermore, the possibility of oral therapy could improve the quality of life of young patients, and could shorten their hospital stay, allowing easier home-care. Even in less dramatic situations quinolones could be justifiable. This is the case in asymptomatic carriers of Neisseria meningitidis. A single oral dose of ciprofloxacin has been shown to be effective in eliminating naso-pharyngeal carriage (Gaunt & Lambert, 1988; Pugsley et al., 1988) . Quinolones could therefore provide an improved actual therapeutic regimen, and the very low necessary dosage (one tablet of 500 mg) should ensure safety.
Thus, the contraindication to quinolones in paediatric practice should not be absolute. Until the real incidence of arthralgic sideeffects in this age group has been better defined, quinolones should be used with discretion in children, infected with quinolone-sensitive micro-organisms, for whom a favourable risk/benefit ratio is foreseeable. FRANCO 
